Prognostic Value of a Composite Score Incorporating Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA-11 PET/CT…

Cohort studyJournal of nuclear medicine : official publication, Society of Nuclear Medicine· Jul 2026

Prognostic Value of a Composite Score Incorporating Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA-11 PET/CT When Screening for [ 177 Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).

Adrien Jougla, Prescillia Nunes, Anne-Laure Giraudet … Clément Drouet

Oncologic ImagingCohort studyPrognosisQ1IF 6.5

PROFILE score stratifies survival in metastatic castration-resistant prostate cancer before [177Lu]Lu-PSMA-617 therapy

Prognostic Value of a Composite Score Incorporating Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA-11 PET/CT When Screening for [ 177 Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).

Adrien Jougla … Clément Drouet

Journal of nuclear medicine · Jul 2026 · Q1 in Radiology

Purpose

We investigated the prognostic value of baseline [ 18 F]FDG and [ 68 Ga]Ga-PSMA-11 PET/CT in patients with metastatic castration-resistant prostate cancer treated with [ 177 Lu]Lu-PSMA-617.

Methods

In this multicenter retrospective study, the associations between several clinical, biologic, and radiologic parameters and overall survival (OS) were tested in a development cohort using univariable analyses, followed by the construction of a multivariable Cox model.

n = 174 patients

0.73

Results

0.73

higher score better predicts survival, 1.0 would be perfect

n = 174 patients

More results

The PROFILE score stratified patients into 3 risk groups and achieved a Harrell C-index of 0.67 (95% CI, 0.62-0.72).

The median OS in the low-, intermediate-, and high-risk groups was 17.2, 13.0, and 8.6 mo, respectively ( P < 0.0001).

“

Conclusion

The PROFILE score offers valuable prognostic information for patients with metastatic castration-resistant prostate cancer when considering the use of [ 177 Lu]Lu-PSMA-617 therapy.

Prognostic Value of a Composite Score Incorporating Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA-11 PET/CT When Screening for [ 177 Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).

Prognostic Value of a Composite Score Incorporating Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA-11 PET/CT When Screening for [ 177 Lu]Lu-PSMA Treatment Eligibility (PROFILE Study).

Related papers